Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 7, Number 2—April 2001
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art

Economic Impact of Antimicrobial Resistance

John E. McGowanComments to Author 
Author affiliation: Emory University School of Medicine, Atlanta, Georgia, USA

Main Article

Table 1

Different perspectives of economic impact of antimicrobial-drug resistancea

Health-care Drug Public
Physician Patient business industry ("society")
Focus Individual Individual Care group Potential clients Population
Outcome Absence of disease Absence of disease Reduce cost of care Product sales Maximize health
Time frame Short Short Short Short, long Long
Motivation Professionalism Personal well-being Profit Profit Social good
Approach Treatment Treatment Cost containment Develop new drugs, maintain life of old drugs Reduce forces leading to resistance

aCordell RL, Solomon SL, Scott RD, McGowan JE Jr, unpub. data.

Main Article

Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."

Page created: May 10, 2011
Page updated: May 10, 2011
Page reviewed: May 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.